Zai Lab Ltd（ZLAB）財務資料ZLABZai Lab Ltd

Zai Lab Ltd (ZLAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ZEJULA, accounting for 30.3% of total sales, equivalent to $32.08M. Other significant revenue streams include VYVGART and NUZYRA. Understanding this composition is critical for investors evaluating how ZLAB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Zai Lab Ltd maintains a gross margin of 60.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -66.40%, while the net margin is -47.81%. These profitability ratios, combined with a Return on Equity (ROE) of -26.91%, provide a clear picture of how effectively ZLAB converts its operational activities into shareholder value.

In the context of the broader market, ZLAB competes directly with industry leaders such as BNTX and UTHR. With a market capitalization of $2.70B, it holds a significant position in the sector. When comparing efficiency, ZLAB's gross margin of 60.25% stands against BNTX's 8.14% and UTHR's 87.30%. Such benchmarking helps identify whether Zai Lab Ltd is trading at a premium or discount relative to its financial performance.

Zai Lab has shown a gross margin of 60.25% in Q2 2026, indicating strong profitability potential despite ongoing losses. The company has also experienced a year-to-date price change of +38.66%, reflecting positive market sentiment.